Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
115.98
+0.38 (+0.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Jazz Pharma Plc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
August 29, 2024
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals.
Via
Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
August 28, 2024
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and...
Via
Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
August 27, 2024
Via
Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
August 23, 2024
Via
Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
August 19, 2024
Via
Benzinga
In a market where value is scarce, NASDAQ:JAZZ offers a refreshing opportunity with its solid fundamentals.
August 08, 2024
Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Decoding 11 Analyst Evaluations For Jazz Pharmaceuticals
August 01, 2024
Via
Benzinga
How Is The Market Feeling About Jazz Pharmaceuticals?
July 15, 2024
Via
Benzinga
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
July 02, 2024
Via
Benzinga
The 3 Best Cannabis Stocks to Buy in August 2024
August 05, 2024
Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment.
Via
Investor's Business Daily
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
July 19, 2024
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Via
InvestorPlace
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
July 11, 2024
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
June 05, 2024
Via
Benzinga
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
July 11, 2024
Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential
July 04, 2024
Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks
Via
InvestorPlace
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Via
InvestorPlace
3 Cannabis Stocks That Could Make Your Grandchildren Rich
June 25, 2024
These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday?
June 20, 2024
Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.
Via
Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
June 20, 2024
The companies are working on treatments for essential tremor, a tricky indication.
Via
Investor's Business Daily
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
June 14, 2024
These blue-chip stocks offer stability, sustainable growth and operational models less prone to wider economic fluctuations.
Via
InvestorPlace
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
June 05, 2024
Via
Benzinga
7 Overlooked Stocks Offering Long-Term Stability From the Shadows
June 03, 2024
These overlooked stocks offer price appreciation, income, and more while diversifying across sectors and company sizes.
Via
InvestorPlace
3 Cannabis Stocks to Buy Now: May 2024
May 26, 2024
These cannabis stocks to buy offer the best odds at capturing long-term upside from current rescheduling initiatives.
Via
InvestorPlace
Topics
Cannabis
Exposures
Cannabis
7 Blue-Chip Stocks to Buy Now: May 2024
May 23, 2024
These blue-chip stocks to buy offer long-term price appreciation opportunities reinforced with undeniable stock stability.
Via
InvestorPlace
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 18, 2024
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
3 Cheap Blue-Chip Stocks to Buy Now: May 2024
May 17, 2024
If stock market speculation isn't quite working in your favor, these cheap blue-chip stocks may be the boost your portfolio needs.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
May 15, 2024
Via
Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.